کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2634077 | 1137122 | 2016 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A Lower-Cost Option for Intrauterine Contraception
ترجمه فارسی عنوان
یک گزینه ارزان قیمت برای تزریق داخل رحمی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
زنان، زایمان و بهداشت زنان
چکیده انگلیسی
In March 2015, the U.S. Food and Drug Administration approved Liletta (Actavis, Dublin, Ireland), a new intrauterine device for contraception. The Centers for Disease Control and Prevention recommend use of long-acting reversible contraception (LARC) as first-line pregnancy prevention. LARC efficacy rates are similar to those of sterilization, with the possibility for quick return of fertility upon removal of the device. Despite benefits and recommendations for this form of contraception, access and high cost remain barriers to use. Liletta is the first lower-cost option for intrauterine contraception. Available to qualified clinics and health centers at a reduced rate, this device may increase availability and decrease the overall cost to women who desire intrauterine contraception.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Nursing for Women's Health - Volume 20, Issue 2, AprilâMay 2016, Pages 197-202
Journal: Nursing for Women's Health - Volume 20, Issue 2, AprilâMay 2016, Pages 197-202
نویسندگان
Kim (graduate student and nurse),